s.beaulieu
TL2 Moderator · Rosario
Contributes reviews on supplier material. Based in Rosario.
Joined 28 February 2025 · last posted 1d
100Posts here
4Topics
0Solutions
1.4kLikes received
1.1kLikes given
25Badges
227Days visited
5kPosts read
Recent activity
Full stream-
Revisiting: The report format the maintainers ask for, and why each field is there Replied, post #109 · Sourcing › Vendor reports · 27 Jul 2026 · 11 likes Blind submission is worth the effort: have someone else relabel the sample so neither you nor the laboratory knows which supplier it came from until the result is back.…
-
I joined for one answer and stayed for a year — what changed my mind Replied, post #108 · Start Here › Welcome · 25 Jul 2026 · 2 likes Off-topic posts that do not belong here belong in the Lounge instead. You are not in trouble if a moderator moves your post — they are just routing it to the right…
-
What to bring: records that a clinician can actually use — a second dataset Replied, post #67 · Clinical › Prescriber conversations · 23 Jul 2026 · 0 likes Clarifying indication: if a compound is approved for diabetes but you have obesity without diabetes, clarify whether your clinician considers this off-label use and…
-
Revisiting: How this community labels and discusses unrefereed work Replied, post #28 · Evidence › Preprints · 18 Jul 2026 · 15 likes Discussing preprints in this community: bring them in for early discussion, label them clearly as preprints, invite peer critique, and be prepared for the discussion to…
-
Stability of BPC-157 in solution: what has been measured — one year on Replied, post #91 · Compounds › Repair & healing peptides · 15 Jul 2026 · 4 likes On post #87 — agreed on the reasoning, with one qualification. For anyone arriving from search engines: this subcategory discusses published preclinical work and the…
-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #63 · Practice › Dosing & titration · 14 Jul 2026 · 18 likes post #62 answers the question as asked. The question underneath it is different. Dose equivalence between different incretin analogues is a weak concept. The molecules…
-
A widely repeated interaction claim that turns out to be unsupported — what changed since Replied, post #84 · Practice › Interactions · 13 Jul 2026 · 3 likes Food interactions: most interactions are absorption interactions. Some medications absorb better with food, others better on an empty stomach. With an incretin agonist…
-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #35 · Start Here › Welcome · 12 Jul 2026 · 17 likes Picking up post #32: that is the part I would want checked first. Introducing yourself is fine and requires no question. Post in this subcategory, describe the context…
-
What to include when your question involves a chromatogram — one year on Replied, post #73 · Start Here › How to Ask · 12 Jul 2026 · 0 likes Chromatogram questions: describe the method first. Column type, gradient, wavelength, detection method. Everything else follows from method. A chromatogram without…
-
Osteoarthritis and mechanical versus metabolic improvement — one year on Replied, post #16 · Clinical › Comorbidities · 10 Jul 2026 · 21 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #6 · Access › Insurance & coverage · 7 Jul 2026 · 0 likes Generic versus brand: most of these compounds do not have generic versions yet. Once they do, formulary coverage and pricing will shift.
-
Substitution between formats during a shortage — what changed since Started this topic · Access › Shortages · 5 Jul 2026 · 5 likes Substitution between formats during a shortage — what changed since — setting out what I have, and where I think it stops being reliable. A coverage question with the…